Dysport in Hallux Abducto Valgus (HAV) Phase IIa

• Status: Completed
• Trial end date: 2020-05-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; Hemagglutinins; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Clinical diagnosis of HAV

• Painful HAV in the study foot at Baseline

Exclusion Criteria:

• Flat or square metatarsal head, metatarsus primus elevates, or severe cavus/planus in the study foot

• Other podiatric or orthopedic condition which would interfere with the evaluation of pain and/or function

• Medical history or clinical evidence of any vascular disease and/or diabetic condition